Blinatumomab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Blinatumomab: From B-Cell Leukaemia Treatment to Primary Release Disorder of Platelets
One-Sentence Summary
Blinatumomab is a bispecific T-cell engager (CD19 x CD3) registered in Singapore as BLINCYTO, and the HSA licence record compiled for this report does not list an approved indication. The TxGNN model predicts it may be effective for primary release disorder of platelets, but 0 clinical trials and 0 publications currently support this direction. This is a model-only prediction with no supporting evidence, and no plausible mechanistic link has been identified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence record |
| Predicted New Indication | Primary release disorder of platelets |
| TxGNN Prediction Score | 95.20% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled records. Based on known pharmacology, blinatumomab is a bispecific T-cell engager that binds CD19 on B cells and CD3 on T cells. This brings T cells to B cells and triggers their destruction.
The predicted conditions, platelet release disorders, are caused by defects in platelet granules or signalling. They are not caused by B-cell disease. The review of this prediction found no mechanistic link. The high score (0.952) reflects the model's network-based inference only. Blinatumomab's own risks, including cytopenias and cytokine release syndrome, could worsen the haematological status of these patients.
Other top-ranked predictions are also hard to justify mechanistically:
| Rank | Predicted Disease | Score | Assessment |
|---|---|---|---|
| 2 | Glanzmann thrombasthenia | 95.02% | Inherited platelet integrin defect, unrelated to B cells |
| 3 | Pseudo-von Willebrand disease | 94.13% | Gain-of-function platelet receptor variant, no link to CD19/CD3 |
| 4 | Drug-induced osteoporosis | 92.70% | Direction of B-cell effect on bone is uncertain; co-administered corticosteroids are a confounder |
| 5 | Severe nonproliferative diabetic retinopathy | 89.25% | Microvascular disease, and T-cell activation is a concern in a chronic non-cancer setting |
| 6 | Psoriasis | 88.92% | T-cell driven, so strong T-cell activation could theoretically worsen it |
| 7 | Ledderhose disease | 88.41% | Fibroproliferative disorder, no link to CD19 |
| 8 | Haemorrhagic disorder due to constitutional thrombocytopenia | 87.88% | Blinatumomab-related cytopenias could worsen bleeding |
| 9 | Penile fibromatosis | 87.80% | Likely reflects shared fibromatosis network features, not a drug-specific mechanism |
| 10 | Bleeding diathesis due to a collagen receptor defect | 87.72% | No known activity on these receptors, and haematological toxicity could aggravate bleeding |
All ten predictions are L5 with no registered trials or literature.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15103P | BLINCYTO POWDER FOR INFUSION 35 MCG/VIAL | Injection, powder, lyophilized, for solution | Not stated in the licence record |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Immunotherapy (bispecific T-cell engager) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions. Cytopenias are a recognised concern. |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Complete blood count, liver and renal function, and monitoring for cytokine release syndrome |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Drug Interactions: The interaction screening returned 100 potential interactions. Examples of those rated Major:
- Bupropion
- Deferiprone
- Iohexol
- Iopamidol
- Samarium (153Sm) lexidronam
Examples of those rated Moderate:
- Warfarin
- Dicoumarol
- Naltrexone
- Theophylline
- Hydrocodone
- Chloramphenicol
Warfarin and dicoumarol deserve particular attention if bleeding-related conditions were ever considered.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The predictions rest only on model scores, with no clinical trials or literature. No credible mechanistic link to platelet disorders exists. Blinatumomab's cytopenia and cytokine release risks could worsen these conditions.
To proceed, the following is needed:
- The package insert from HSA, covering warnings, contraindications and the approved indication
- Mechanism of action data from DrugBank
- A plausible biological rationale and preclinical evidence linking CD19/CD3 engagement to the predicted condition
- A benefit-risk assessment for non-cancer use, including cytokine release syndrome and cytopenias
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.